Denali Capital Acquisition Corp. has announced an update to its merger agreement with Semnur Pharmaceuticals, Inc., a Delaware corporation and wholly owned subsidiary of Scilex Holding Company. Originally entered into on August 30, 2024, the agreement has been amended as of April 16, 2025. According to the updated terms, Denali's subsidiary, Denali Merger Sub Inc., will merge with Semnur, with Semnur continuing as a wholly owned subsidiary of Denali. This merger is part of the larger business combination between the involved parties.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Capital Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-068263), on July 28, 2025, and is solely responsible for the information contained therein.